Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Necessary Expansion of the Management Board at Rentschler Biotechnologie

Published: Thursday, November 08, 2012
Last Updated: Wednesday, November 07, 2012
Bookmark and Share
Frank Ternes to become Managing Director of Sales at Rentschler.

The family-owned business based in Laupheim has expanded its management board. As a contract manufacturing organization, Rentschler Biotechnologie GmbH performs research on, develops, and produces biologicals for its international clientele.

Reiner Winkelbauer, who has been the company's Commercial Manager for the past four years, was appointed Managing Director of Finances.

He was previously the Controlling and Chief Financial Officer of AEG in Ulm and later became the Commercial Manager at EADS also in Ulm.

Since September 1, 2012, Thomas Siklosi has strengthened the management board in the GMP Operations area. Before he started working at Rentschler Biotechnologie as manager of the Active Substance Department in 1984, Siklosi worked for Boehringer Mannheim for 10 years. In 2008, he took over the management of GMP Operations at Rentschler.

In the future, Siklosi will also be responsible for the "operational excellence" program at Rentschler that will focus on customer needs and on optimizing quality and efficiency.

Starting from November 1, 2012, he will be actively supported by Luca Dellacroce, the "new face" in Rentschler's management board. In the past, Dellacroce worked for notable companies such as Motorola and Nokia in process optimization.

Frank Ternes will also be a new addition to the management level at Rentschler beginning February 1, 2013.

After 25 years at Boehringer Ingelheim where he last served as Senior Vice President of Biopharmaceutical Contract Manufacturing, Ternes will now become Managing Director of Sales at Rentschler.

Dr. Nikolaus F. Rentschler, CEO and owner, explains the necessary changes that led to a larger management board as follows:

"To accommodate the rapid growth of the company during the past 10 years, the management board had to also "grow." Internal processes must be constantly reconsidered and optimized in order to serve our customers even better and more efficiently. For this reason, I decided to implement the necessary steps to achieve process optimization in my company. I wish Messrs. Winkelbauer, Siklosi, Dellacroce, and Ternes the strength and fortitude, as well as the determination and perseverance to act in the interests and for the success of my company."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!